Literature DB >> 30217295

Surgical treatment of pNET - Experience of a "high-volume" center.

Florian Bösch1, Katharina Hofmann1, Michaela Coenen2, Sebastian Pratschke1, Michael Thomas1, Thomas Knösel3, Christiane J Bruns4, Markus Guba1, Jens Werner1, Martin K Angele5.   

Abstract

BACKGROUND: Neuroendocrine tumors of the pancreas (pNETs) are a rare disease. Grading according to the Ki67-index is the most validated risk factor. Nevertheless, controversies exist concerning other prognostic factors. The aim of this study was to evaluate published risk factors.
METHODS: Patients with pancreatic NETs who underwent surgery at our department from 2000 to 2014 were analyzed. The patient and tumor characteristics were evaluated. Kaplan-Meier analyses, univariate calculations as well as multivariate analyses were performed.
RESULTS: In total, 98 patients underwent surgery due to a pNET. The final study population consisted of 88 patients. Univariate analysis demonstrated that overall survival is influenced by tumor grading, local resection margin and presence of distant metastases. However, in the multivariate analysis, only grading and the resection margin had prognostic significance. The size of the primary tumor directly correlated with the probability of metastases. Multivisceral operations had no influence on morbidity or mortality.
CONCLUSIONS: Resection of pNETs is the only curative treatment and is safe. Since the incidence of pNETs is low, treatment should be performed at a high-volume center.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Multivisceral operation; Neuroendocrine tumor; Pancreas; Prognostic factor

Mesh:

Year:  2018        PMID: 30217295     DOI: 10.1016/j.suronc.2018.05.027

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

3.  Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection.

Authors:  Florian Bösch; Harun Ilhan; Vanessa Pfahler; Michael Thomas; Thomas Knösel; Valentin Eibl; Sebastian Pratschke; Peter Bartenstein; Max Seidensticker; Christoph J Auernhammer; Christine Spitzweg; Markus O Guba; Jens Werner; Martin K Angele
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

4.  A proof-of-concept methodology to validate the in situ visualization of residual disease using cancer-targeted molecular agents in fluorescence-guided surgery.

Authors:  Servando Hernandez Vargas; Christie Lin; Solmaz AghaAmiri; Julie Voss; Naruhiko Ikoma; Hop S Tran Cao; Sukhen C Ghosh; Adam J Uselmann; Ali Azhdarinia
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2020-02-19

5.  Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors.

Authors:  Florian Bösch; Alexandr V Bazhin; Sabine Heublein; Katharina Brüwer; Thomas Knösel; Florian P Reiter; Christoph J Auernhammer; Markus O Guba; Christine Spitzweg; Jens Werner; Martin K Angele
Journal:  BMC Cancer       Date:  2019-06-13       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.